BioSyent Pharma to Introduce Gelclair® at AHNS 11th International Conference on Head and Neck Cancer
07 July 2023 - 7:53AM
BioSyent Pharma Inc. (“BioSyent Pharma”), a subsidiary of BioSyent
Inc. (“BioSyent”, “the Company”, TSX Venture: RX), is attending the
American Head and Neck Society (AHNS) 11th International Conference
on Head and Neck Cancer in Montreal, Quebec on July 8-12, 2023 to
promote Gelclair®, its new oncology supportive care product.
Gelclair®, indicated for the relief of the painful symptoms of oral
mucositis, was in-licensed by BioSyent Pharma in December 2022 and
was approved by Health Canada in May 2023. BioSyent Pharma is
commencing the promotional launch of Gelclair® in Canada and is
planning to have the product available to Canadians in the fourth
quarter of 2023.
“We are pleased to begin promoting Gelclair® in
Canada,” said René Goehrum, President and CEO of BioSyent. “This
innovative product can make a difference in the quality of life of
Canadian cancer patients suffering from oral mucositis. Gelclair®
represents BioSyent’s first product in the oncology supportive care
therapeutic area as we continue to focus on our strategic
priorities of portfolio diversification and growth.”
About Oral Mucositis
Oral mucositis is a painful condition often
experienced by patients undergoing radiation or chemotherapy for
cancer or bone marrow transplant. It is an inflammation and
ulceration of the mucous membranes in the mouth and throat.
Dr. Murali Rajaraman, Chair of the Atlantic
Canada Radiation Medicine Council (ACRM) and Associate Professor at
Dalhousie University’s Department of Radiation Oncology, stated
that “Oral mucositis is an important problem that can result in
severe mouth pain making it difficult to eat, drink, swallow and,
in some cases, even speak. It can significantly affect a cancer
patient’s quality of life and may lead that patient to delay or
stop their cancer treatment. The prevention and management of oral
mucositis remains a significant challenge for patients and their
healthcare providers. It will be beneficial to have another product
option available to patients to better manage oral mucositis.”
About
Gelclair®
Gelclair® is a protectve gel that is indicated
for the rapid relief of the painful symptoms of oral mucositis. It
forms a barrier that adheres to the mucosa of the mouth, protecting
and hydrating damaged tissue, shielding the exposed nerves from
painful stimuli while eating and drinking, and thereby providing
patients with fast pain relief.
Clinical studies have shown that Gelclair®
provides fast acting pain relief, supports healing, and improves
the ability of patients suffering from oral mucositis to eat,
drink, swallow and speak. Studies have also reported a decreased
need for analgesics or opioids to reduce the pain of oral
mucositis, as well as reductions in the grade of severity of oral
mucositis with the use of Gelclair®. Gelclair® has demonstrated
significantly better patient tolerability and acceptance than the
standards of care it was compared to, helping patients to continue
with their cancer treatments. Gelclair® has no known pharmaceutical
interactions and only rare, non-serious, reversible adverse events
have been reported. Gelclair® has demonstrated its safety and
efficacy in helping to protect cancer patients from the severe pain
associated with oral mucositis caused by radiotherapy or
chemotherapy.
To learn more about Gelclair®, please visit:
www.gelclair.ca
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these
patients by marketing its products through its community, specialty
and international business units.
As of the date of this press release, the
Company has 11,891,961 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
This press release may contain information or
statements that are forward-looking. The contents herein represent
our judgment, as at the release date, and are subject to risks and
uncertainties that may cause actual results or outcomes to be
materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to,
those associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024